Felcisetrag stimulates 5-HT4-serotonin receptors in the human atrium
Open Access
- 29 September 2025
- journal article
- research article
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 399 (3) , 3429-3445
Abstract
Felcisetrag (methyl 4-[[4-[[(2-propan-2-yl-1 H -benzimidazole-4-carbonyl)-amino]-methyl]-piperidin-1-yl]methyl]piperidine-1-carboxylate, TD-8954, TAK-954) has a structural formula with similarity to serotonin. It is one of the most potent compounds to bind to recombinant human 5-HT 4 -serotonin receptors. We noted that felcisetrag raised force of contraction in left atrial preparations (LA) and beating rate in right atrial preparations (RA) from mice with cardiac-specific overexpression of the human 5-HT 4 receptors (5-HT 4 -TG) but was inactive in LA and RA from adult wild type mouse hearts (WT). When felcisetrag had increased force of contraction in LA or beating rate in RA of 5-HT 4 -TG, GR125487, a 5-HT 4 receptor antagonist, reduced force of contraction and beating rate. Felcisetrag raised force of contraction only in the presence of cilostamide in human right atrial preparations (HAP) obtained from adult patients during open heart surgery due to severe coronary heart disease. These positive inotropic effects of felcisetrag in HAP were attenuated by 1 µM GR125487. In the presence of cilostamide, 100 nM felcisetrag exerted positive inotropic effects that were increased further by 1 µM serotonin. When 1 µM serotonin had raised force of contraction, additionally applied 100 nM felcisetrag reduced force of contraction in HAP. These data suggest that felcisetrag can act as an agonist as well as an antagonist at human 5-HT 4 receptors in the mammalian heart.Keywords
Funding Information
- Martin-Luther-Universität Halle-Wittenberg
This publication has 52 references indexed in Scilit:
- The Effect of Hepatic Impairment on the Pharmacokinetics of Intravenously Administered Felcisetrag (TAK‐954)The Journal of Clinical Pharmacology, 2022
- Evaluation of the Pharmacokinetics of Felcisetrag (TAK‐954), a 5‐HT4 Receptor Agonist, in the Presence and Absence of Itraconazole, a Potent CYP3A4 InhibitorClinical Pharmacology in Drug Development, 2022
- Cardiovascular effects of cisapride and prucalopride on human 5-HT4 receptors in transgenic miceNaunyn-Schmiedeberg's Archives of Pharmacology, 2018
- Human 5-HT4 receptor stimulation in atria of transgenic miceNaunyn-Schmiedeberg's Archives of Pharmacology, 2013
- Methylxanthines in Asthma2010
- Phosphorylation of phospholamban and troponin I through 5-HT4 receptors in the isolated human atriumNaunyn-Schmiedeberg's Archives of Pharmacology, 2008
- Functional serotonin 5-HT4 receptors in porcine and human ventricular myocardium with increased 5-HT4 mRNA in heart failureNaunyn-Schmiedeberg's Archives of Pharmacology, 2004
- Targeted Overexpression of Phospholamban to Mouse Atrium Depresses Ca2+Transport and ContractilityJournal of Molecular and Cellular Cardiology, 1998
- L-type calcium channel activity in human atrial myocytes as influenced by 5-HTNaunyn-Schmiedeberg's Archives of Pharmacology, 1993
- The gastrointestinal prokinetic benzamide derivatives are agonists at the non-classical 5-HT receptor (5-HT4) positively coupled to adenylate cyclase in neuronsNaunyn-Schmiedeberg's Archives of Pharmacology, 1989